This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 747789
Download Presentation The PPT/PDF document "PARP Inhibitors and Cancer: What Do Y..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
PARP Inhibitors and Cancer: What Do You Need to Know?Slide2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide3
Poly(ADP-ribose) PolymerasesSlide4
PARP Involvement in DNA RepairSlide5
Challenges to the ModelSlide6
Alternative Models of PARP
InhibitionSlide7
Alternative Models of PARP Inhibition (cont)Slide8
PARP InhibitorsSlide9
Differences Among PARP InhibitorsSlide10
Single Agent DevelopmentSlide11
"Study 42": Single Agent OlaparibSlide12
Talazoparib Phase 1Slide13
Talazoparib Phase 2 (ABRAZO) Slide14
OlympiAD Study DesignSlide15
Primary Endpoint: PFS by BICRSlide16
Objective Response by BICRSlide17
Adverse Events (Any Grade) in ≥15%
of Patients Slide18
BROCADE Trial DesignSlide19
BROCADE Trial: Tumor ResponseSlide20
BROCADE Trial: PFSSlide21
Phase 1 Trial of Olaparib and CisplatinSlide22
PARP Inhibitor With PI3K Inhibitor for BRCA1-
Related Breast CancerSlide23
OlympiA: Olaparib in High-Risk Germline
BRCA
MutationsSlide24
Possible Role of PARP Inhibitor Therapy in Other Settings Slide25
Mechanisms of ResistanceSlide26
Platinum Cross-Resistance?Slide27
Conclusions and SummarySlide28
AbbreviationsSlide29
Abbreviations (cont)Slide30
Abbreviations (cont)